anti-CD19 CAR T cells AT101
Term · Oncology and biomedicine · MLC-T-ONC-010251
A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 CAR T cells AT101 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
| Identifier | MLC-T-ONC-010251 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-CD19 CAR-T cells AT101 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010251",
"term": "anti-CD19 CAR T cells AT101",
"field": "Oncology and biomedicine",
"definition": "A preparation of T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 CAR T cells AT101 recognize and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.",
"synonyms": [
"anti-CD19 CAR-T cells AT101"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-cd19-car-t-cells-at101/"
}
Record 1,336 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.